Summit Therapeutics PLC (NASDAQ:SMMT – Get Free Report) shares hit a new 52-week low on Monday after Citigroup lowered their price target on the stock from $43.00 to $42.00. Citigroup currently has a buy rating on the stock. Summit Therapeutics traded as low as $12.01 and last traded at $12.6040, with a volume of 1,698,713 shares changing hands. The stock had previously closed at $14.15.
Several other research analysts have also recently issued reports on the stock. Barclays lowered their target price on shares of Summit Therapeutics from $20.00 to $18.00 and set an “equal weight” rating for the company in a report on Monday. Sanford C. Bernstein reiterated a “market perform” rating on shares of Summit Therapeutics in a research note on Monday, October 5th. Summit Redstone set a $25.00 price target on shares of Summit Therapeutics in a research note on Wednesday, September 9th. Leerink Partners raised shares of Summit Therapeutics from an “underperform” rating to a “market perform” rating and boosted their price target for the company from $12.00 to $13.00 in a research report on Wednesday, August 12th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Summit Therapeutics in a research note on Tuesday, September 22nd. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $28.38.
View Our Latest Report on SMMT
Latest Summit Therapeutics News
These are some of the SMMT news items that stood out recently:
- Positive Sentiment: Citigroup maintained a Buy rating while trimming its price target from $43 to $42, signaling that the analyst sees potential despite the regulatory setback. Citigroup rating
- Neutral Sentiment: Barclays lowered its price target from $20 to $18 and kept an Equal Weight rating. Separately, call-option trading surged, indicating unusually active but directionally uncertain investor positioning. Barclays rating
- Negative Sentiment: The FDA issued a Complete Response Letter and declined to approve ivonescimab for lung cancer. Reports say the agency found the overall-survival evidence insufficient despite positive progression-free-survival results. The decision clouds the drug’s regulatory path and contributed to shares falling to a 52-week low. Reuters report Zacks report
Hedge Funds Weigh In On Summit Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. IFP Advisors Inc raised its stake in Summit Therapeutics by 792.3% during the 3rd quarter. IFP Advisors Inc now owns 1,508 shares of the company’s stock valued at $26,000 after acquiring an additional 1,339 shares during the last quarter. Toth Financial Advisory Corp purchased a new position in shares of Summit Therapeutics in the 3rd quarter valued at approximately $30,000. CX Institutional grew its stake in shares of Summit Therapeutics by 244.8% in the 3rd quarter. CX Institutional now owns 2,038 shares of the company’s stock valued at $34,000 after purchasing an additional 1,447 shares during the last quarter. Global Retirement Partners LLC grew its stake in shares of Summit Therapeutics by 200.0% in the 3rd quarter. Global Retirement Partners LLC now owns 2,058 shares of the company’s stock valued at $35,000 after purchasing an additional 1,372 shares during the last quarter. Finally, Eurizon Capital SGR S.p.A. acquired a new position in shares of Summit Therapeutics in the third quarter valued at approximately $34,000. Hedge funds and other institutional investors own 4.61% of the company’s stock.
Summit Therapeutics Stock Down 9.7%
The stock has a fifty day moving average price of $16.16 and a 200-day moving average price of $16.09.
About Summit Therapeutics
Summit Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its lead candidate is ivonescimab, a bispecific antibody designed to target both PD-1 and VEGF, two pathways involved in tumor growth and the immune response. The company is evaluating the treatment in clinical trials for multiple types of cancer. Summit licensed rights to develop and commercialize ivonescimab from China-based Akeso in 2022. Summit’s licensed territory covers markets outside China, including the United States, Canada, Europe and Japan.
Featured Stories
- Five stocks we like better than Summit Therapeutics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
